GRIA4

Across TCGA pan-cancer cohorts, GRIA4 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated GRIA4 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher GRIA4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GRIA4 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

OV, LIHC, and UCEC are the cancer types where GRIA4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.245	0.696	<.001	36	view →
LIHC	DFS	Median	All	0.260	0.553	<.001	27	view →
UCEC	DFS	Median	All	0.816	0.614	.006	26	view →
LUAD	OS	Median	II,III,IV	0.158	0.750	<.001	18	view →
STAD	DFS	Median	III,IV	1.000	0.333	.015	15	view →
ESCA	OS	Median	II,III,IV	0.103	0.868	<.001	12	view →
TGCT	DFS	Median	All	0.014	0.837	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

GRIA4–OV (OS)

Open the OV breakdown →